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The intrinsic period of circadian clocks is their defining
adaptive property. To identify the biochemical mech-
anisms whereby casein kinase1 (CK1) determines cir-
cadian period in mammals, we created mouse null and
tau mutants of Ck1 epsilon. Circadian period length-
ened inCK13/, whereas CK13tau/taushortened circa-
dian period of behavior in vivo and suprachiasmatic
nucleus firing rates in vitro, by accelerating PERIOD-
dependent molecular feedback loops. CK13tau/tau
also accelerated molecular oscillations in peripheral
tissues, revealing its global role in circadian pacemak-
ing. CK13tau acted by promoting degradation of both
nuclear and cytoplasmic PERIOD, but not CRYPTO-
CHROME, proteins. Together, these whole-animal
and biochemical studies explain how tau, as a gain-
of-function mutation, acts at a specific circadian
phase to promote degradation of PERIOD proteins
and thereby accelerate the mammalian clockwork in
brain and periphery.
INTRODUCTION
In mammals, daily rhythms of sleep and metabolism are driven
by the circadian pacemaker within the suprachiasmatic nuclei
of the hypothalamus (SCN) which coordinates the activity of sub-
ordinate circadian clocks in other brain regions and in peripheral
tissues (Reppert and Weaver, 2002; Hastings et al., 2003; Low-
rey and Takahashi, 2004; Saper et al., 2005). Precise mainte-
nance of circadian period is the defining adaptive property of
these clocks. In both brain and periphery, a central concept is
that circadian clocks consist of interlocked autoregulatory feed-
back loops in which CLOCK:BMAL1 heterodimers bind to E box78 Neuron 58, 78–88, April 10, 2008 ª2008 Elsevier Inc.DNA sequences contained within genes encoding the transcrip-
tional repressors PER and CRY. Following their accumulation in
the cytoplasm, PER:CRY complexes translocate to the nucleus
after a delay of several hours and repress the activity of con-
stitutively bound CLOCK:BMAL1 complexes. These inhibitory
complexes are then degraded following a further delay, and
the derepression of CLOCK:BMAL1 activity initiates the next cir-
cadian cycle of Per and Cry transcription. Mutations in various
elements of this core molecular clock have been described,
many of which result in either arrhythmia or alteration in period
of rest/activity and sleep cycles.
In addition toperiodic transcription,posttranslationalmodifica-
tions of clock proteins are crucial for the correct operation of mo-
lecular clockworks (Lee et al., 2001; Gallego and Virshup, 2007).
In particular, reversible phosphorylation provides a potential
mechanism for the regulated formation of protein complexes,
their nuclear entry, and ultimate degradation via ubiquitination
pathways, each step of which introduces delays into the feed-
back loop. Current interest has focused on the role that protein
phosphorylationmayplay in tuning thecircadianoscillator toape-
riod of 24 hr. In Drosophila, mutations of CK1 (doubletime, DBT)
were the first circadian mutants discovered to involve an enzyme
and resulted in either short (dbts) or long (dbtl) rhythmsof eclosion
and locomotor activity (Kloss et al., 1998; Price et al., 1998).
The tau mutation of Syrian hamsters was the first mammalian
circadian mutation discovered. It causes significant shortening
of activity cycles to 20 hr and assorts in a Mendelian fashion
(Ralph and Menaker, 1988). Subsequent mapping studies
revealed that this mutation resided within casein kinase 13 as
a C to T transversion in position 178 (Lowrey et al., 2000). Protein
expression studies suggested a destabilization of nuclear PER in
the tau mutant hamster (Dey et al., 2005), while recent modeling
and biochemical studies suggested that tau is a gain-of-function
mutation on specific residues within the PER protein target (Gal-
lego and Virshup, 2007), likely leading to increased degradation,
altered stability, and accelerated protein turnover. It is unknown
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mathematical modeling studies, reflect the real circumstances in
living animals. Further, it is unclear whether altered degradation
of PER involves cellular compartmentalization, whether it is
tissue specific (neural versus peripheral), and ultimately how it
leads to accelerated molecular timing in the SCN.
To define the role of CK13 in the circadian clockwork, and
hence the molecular disturbance underlying advanced sleep
phase disorder and accelerated circadian period, we describe
here the generation of a mouse model of the hamster tau muta-
tion within CK13 . We adapted the loxP-cre strategy to produce
mice carrying the tau allele of the Ck13 gene and used subse-
quent cre-mediated in vivo disruption of exon 4, which encodes
the catalytic domain of CK13 (Lowrey et al., 2000) to generate
aCk13 null allele. This allelic series was assayed by circadian be-
havioral wheel-running and SCN electrophysiological studies
and revealed that tau acts as a gain-of-function mutation, short-
ening period in a dose-dependent manner. By using PER2
protein reporters (Yoo et al., 2004), we also define, for the first
time, the impact of this mutation on the molecular dynamics of
both the SCN and peripheral timers and, within the SCN, high-
light the role of accelerated protein turnover in shortening circa-
dian period and activity/rest cycles. Finally, western blotting and
imaging studies of both transfected cell lines, primary fibroblasts
and SCN tissue derived from CK13tau mice reveal that CK13tau
specifically targets PERIOD but not CRY proteins during the
early nocturnal phase of the circadian cycle, acting on one com-
ponent of the negative feedback element of the clock, and lead-
ing to an acceleration of period by an asymmetric degradation of
PER proteins at a specific phase of the circadian cycle.
RESULTS AND DISCUSSION
Generation of a tau Mutant Allele for CK13
and Subsequent Disruption
We adapted the loxP-cre recombinase strategy used for creating
a conditional knockout to produce a mouse carrying the tau allele
of the Ck13 gene. This can be subsequently converted in vivo to
a CK13 gene knockout by cre-mediated ablation of exon 4, which
encodes the catalytic domain of CK13 (Lowrey et al., 2000; see
FigureS1Aavailableonline).Deletionofexon4 leads toa frameshift
and premature stop codon. The linearized targeting vector was
electroporated into ES cells andG418 resistant, homologously re-
combined ES clones (Figure S1B) subjected to transient transfec-
tion with cre recombinase followed by FIAU selection. Resistant
colonies that had deleted the selection cassette but retained the
mutant tau exon were identified by PCR (Figure S1C) and used
to generate germline transmitting chimeras. The presence of the
tau mutation (the C to T transversion at amino acid position 178)
in the founder transgenic mice was confirmed by sequencing of
animal-derived genomic DNA through the tau site (Figure S1D).
F1 mice carrying the floxed tau allele were crossed with a deletor
cre mouse to generate the Ck13 knockout line. Gene knockout
was confirmed genetically by genomic DNA sequencing of the
Ck13 gene as well as by RT-PCR using brain cDNA as templates
(Figure S1E). The absence of theCK13 protein was also confirmed
by western blotting in whole-brain extracts using an antibody
against the C terminus of CK13 (Figure S1F). Mice carrying thetau allele (tau/+ and tau/tau) or the knockout allele (/+ and /)
were viable and fertile with no overt deleterious phenotype.
The tau Mutation Shortens and the Null Mutation
of CK13 Lengthens Period
All wild-type and knockout mice entrained to LD 12 hrL:12 hrD
exhibited activity in the dark phase, commencing shortly after
lights off. In contrast, tau mice exhibited variable responses to
LD 12L:12D cycles, and in a sample of 30 animals, 9 exhibited
a phase advance of the LD cycle, 5 exhibited masking with on-
sets coincident with dark onset, and 16 animals free-ran across
the prevailing LD cycle (Figures S2A–S2C). To determine the
impact of CK13tau on free-running behavior, we monitored
wheel-running activity in constant darkness (DD). CK13tau mice
exhibited significant shortening of period in a dose-dependent
manner (Figures 1A and 1B): 23.6 ± 0.05 hr for wild-type (WT),
21.8 ± 0.08 hr for heterozygote (CK13tau/+), and 20.0 ± 0.07 hr
for homozygotes (CK13tau/tau). This is equivalent to 1.80 hr/copy
of CK13tau and virtually identical to the behavioral phenotype of
this mutation in Syrian hamsters (6). In contrast, knockout mice
exhibited a small but significant period lengthening compared
to their WT counterparts (24.0 ± 0.06 versus 23.6 ± 0.05 hr, re-
spectively, p < 0.001; Figures 1A and 1B). Importantly, mice car-
rying a single copy of the knockout allele exhibited a WT-like
free-running period of 23.7 ± 0.05 hr, while the tau hemizygote
(CK13tau/, 21.6 ± 0.09 hr) and heterozygote (CK13tau/+) mice ex-
hibited virtually identical periods (Figures 1A and 1B). This shows
that a single WT copy of Ck13 provides little protective effect in
the face of a tau allele and thus offers definitive genetic evidence
that tau acts as a gain-of-function mutation.
Interestingly, the absolute number of wheel revolutions per
circadian cycle was similar in all genotypes, suggesting period
acceleration in the taumutants may occur due to an asymmetric
effect on overall circadian organization, perhaps sparing noctur-
nal activity per se (Figures 1C and 1D). Similar effects are
reported for circadian mutations in DBT (Price et al., 1998),
the CK1 ortholog in Drosophila. The asymmetric acceleration
of circadian timing was extended in studies ofmetabolic rhythms
in the CK13tau and WT mice using indirect calorimetry. Here, we
noted that there was a compression of circadian rhythms of ox-
ygen consumption (VO2) in CK13
tau mice which closely matched
the periods determined earlier by wheel running (Figure 2).
Remarkably, the pattern of oxygen consumption was highly
asymmetric such that the shortening of period was almost en-
tirely associatedwith a compression of the inactive (subjectiveday)
phase (active phase duration, WT = 12.6 ± 0.1 hr; CK13tau =
13.4 ± 0.6 hr; inactive phase duration, WT = 11.4 ± 0.1 hr;
CK13tau = 6.9 ± 0.5 hr; p < 0.01; Figures 2B and 2C). Hence,
our data suggest that the absolute duration of nocturnal physiol-
ogy and behavior were unaffected by the CK13tau mutation,
rather, nocturnal events were initiated earlier in CK13tau than in
WT. Such observations are compatible with our earlier demon-
stration in tau mutant hamsters of an advanced onset of circa-
dian nocturnal melatonin secretion, with the result that overall
duration of secretion of this nocturnal hormone is identical to
that of wild-types (Lucas et al., 1999). Collectively, these data
suggest that CK13tau may accelerate period by compressing
a specific phase of the circadian behavioral and physiologicalNeuron 58, 78–88, April 10, 2008 ª2008 Elsevier Inc. 79
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Accelerated Molecular Clockwork in tau Mutant MiceFigure 1. Locomotor Activity Rhythms for Wild-Type, tau Mutant, and Knockout Mice
(A) Representative wheel-running activity records (actograms) for wild-type (CK13+/+; top-left panel), heterozygous (CK13+/tau; top-middle panel), homozygous
(CK13tau/tau; top-right panel), hemizygous (CK13+/; bottom-left panel), hemizygous tau (CK13tau/; bottom-middle panel), and CK13 knockout mice (CK13/;
bottom-right panel) are shown in double-plotted format. Each horizontal line represents 48 hr, with the second day plotted to the right and one cycle below
the first cycle. Animals were run in 24 hr cycles of 12 hr Light, 12 hr Dark (LD) and then in continuous darkness (DD). The timing of the LD cycles is indicated
by the alternating white and gray areas of the actogram.
(B) Periodogram estimates of period for each genotype as mean ± SEM; the number of animals is indicated within each bar. Bars with different letters show a
significant difference (p < 0.001 ANOVA and post-hoc Bonferroni compared to wild-type); bars with the same letter are not significantly different.
(C) Circadian amplitude (power from periodogram analyses) for each genotype. There was no significant difference between genotypes (mean ± SEM).
(D) Activity levels during the first 4 weeks of DD for each genotype as determined by total wheel-running revolutions per circadian cycle. There were no significant
differences between genotypes despite shortened overall circadian period (mean ± SEM).cycle. In the case of the knockout mice, the circadian phenotype
was mild (ca 18 min extension in period). Although we have not
undertaken measures of oxygen consumption in knockout
mice, our analysis of the relative proportion of the circadian cycle
in which knockout animals are active (alpha) and the overall
structure of the circadian activity cycle revealed that they were
not significantly different to wild-types.
Individual Neurons of the SCN Exhibit an Accelerated
Firing Rate in CK13tau Mutants
In order to extend our studies to the SCN, we adopted the use of
a suction electrodemethodwhich permits discrimination of firing80 Neuron 58, 78–88, April 10, 2008 ª2008 Elsevier Inc.rate profiles for individual cells for over 48 hr in vitro (Brown et al.,
2006). Using acutely prepared SCN slices, we recorded extracel-
lular multiunit electrical activity in animals in which circadian
periods had previously been recorded in running wheels in DD,
permitting comparison of individual behavioral periods to SCN
cellular rhythms. In all genotypes (CK13+/+, CK13tau/+, CK13tau/tau,
CK13/), there was a close concordance with their period of
multiunit recording in each slice (Figure 3A). SCN single-unit
recordings revealed a similar outcome (Figure 3A), with a highly
significant correlation (r2 = 0.83, p < 0.01) between rhythms of
single unit firing rates and behavior across all four genotypes
(Figure 3B), indicating that effects of CK13tau on behavioral
Neuron
Accelerated Molecular Clockwork in tau Mutant Miceperiod likely arose from corresponding changes in circadian pat-
terns of electrical activity of SCN neurons (Brown et al., 2005).
The pattern of electrical activity of the knockout was normal in
terms of amplitude and firing frequency, indicating that gene
loss did not alter fundamental aspects of SCN electrophysiolog-
ical properties. Thus, our generation of CK13tau in mice and sub-
sequent gene deletion has resulted in a novel allelic series of cir-
cadian period, ranging from20.0 (CK13tau/tau) to 24.0 hr (CK13/),
and provides an unprecedented resource to explore the central
role of CK1 to circadian rhythm regulation in mammals.
Impact of CK13tau/tau on the Molecular Pacemaker
of the SCN and Peripheral Tissues
Accelerated circadian periods of activity/rest cycles and also
SCN firing rates likely reflect altered dynamics within molecular
feedback loops that underpin circadian time-keeping within
the SCN. To determine the impact of CK13 on SCN molecular
oscillators, CK13tau mice were crossed into PER2::Luciferase
(PER2::LUC) protein fusion reporter mice (Yoo et al., 2004). Or-
ganotypic SCN slices were prepared from 5- to 10-day-old
pups and luciferase activity recorded using photomultiplier
tubes (PMTs) over a minimum of 7–10 cycles. Bioluminescence
recorded from PER2::LUC SCN slices closely matched behav-
ioral rhythms for each genotype (Figures 4A and 4B): 24.4 ±
0.15 hr, 21.9 ± 0.08 hr, and 20.2 ± 0.17 hr in CK13+/+,
CK13tau/+, CK13tau/tau slices, respectively (ANOVA, F = 226.5,
p < 0.01). To extend these studies to the single-cell level,
we recorded PER2 expression of individual SCN neurons
Figure 2. CK13tau Causes Asymmetric Acceleration of Circadian
Timing in Metabolic Rhythms
(A) Representative recordings of oxygen consumption rhythms (VO2) in
WT (red) and Tau mutant (blue) mice across a segment of the light-dark
(LD) and constant light (LL) cycles, showing an accelerated period in
Tau mice. * indicates cages cleaned.
(B) Representative profiles of VO2 for Tau and WT normalized to the
midpoint (50%) of the trough-to-peak and peak-to-trough amplitudes.
Rhythms are double plotted over a 48 hr time base. The ‘‘active’’ and ‘‘in-
active’’ portions of the cycle were defined as the portions of the cycle
above or below zero (respectively).
(C) Duration of the active (black) and inactive (open) phases of the circa-
dian cycle (mean ± SEM). Duration of active phase was maintained in
Tau mice in both LD and LL, when compared with WT mice. In contrast,
the inactive (subjective day) portion of the cycle was reduced in
Tau mice under both light conditions. As expected, both genotypes
exhibited a lengthening of the inactive period when switched from LD to
LL. (**p < 0.01 post-hoc Bonferroni).
measured using a CCD camera. Single-neuron imaging
showed that circadian period of single neurons also
matched genotype (24.9 ± 0.09, 22.1 ± 0.04, and 20.5 ±
0.05 hr for CK13+/+, CK13tau/+, CK13tau/tau, respectively)
and that CK13tau had no effect on the intercellular syn-
chrony nor regional distribution of circadian gene expres-
sion across the SCN (Figure 4C). Therefore, these biolumi-
nescence recordings reveal that both the behavioral and
electrophysiological impact of the CK13tau mutation is
underpinned by accelerated molecular time-keeping within
individual SCN neurons.
It is unknown whether endogenous CK13 has a global role in
setting clock speed in tissues outside the nervous system. We
therefore recorded circadian PER2::LUC activity in organotypic
slices of pituitary, lung, and kidney and primary lung fibroblast
cultures. This revealed clear circadian expression of PER2 and,
on a group basis, a significant shortening of period by CK13tau
(Figures S3A, 4B, and 4D). In contrast to the SCN, however,
the magnitude of effect was variable across tissues, indicating
partial penetrance of themutation. Moreover, in lung and kidney,
the tau allele significantly accelerated the rate of damping of the
molecular cycle (Figure S3B). Thus, our in vitro data show that
CK13tau accelerates pacemaking globally, although its detailed
impact on SCN and peripheral oscillators is tissue specific.
We hypothesized from our tau mutant hamster studies that
CK13tau may shorten period by accelerating the loss of nuclear
PER proteins specifically in the early nocturnal phase (Dey
et al., 2005), leading to earlier derepression of BMAL1 and
CLOCK and overall circadian acceleration. This ‘‘asymmetric ac-
celeration’’ model of PER protein turnover in CK13tau mutants
was tested in our bioluminescence recordings of SCN slices.
By aligning SCN waveforms from WT and CK13tau (Figure 4E)
by either peak or nadir of expression, it is evident that the muta-
tion significantly accelerates the decline of PER2::LUC (time
to fall to 50% level WT = 5.3 ± 0.3 hr, CK13tau/tau = 3.9 ± 0.2 hr,
ANOVA F = 8.97, p < 0.01). Consequently, the cycle in CK13tau
homozygote slices is advanced by ca 3.4 hr compared to WT
over the interval of PER protein decline (hours from peak to
trough), whereas over the rising phaseCK13tau/tau has little effect.Neuron 58, 78–88, April 10, 2008 ª2008 Elsevier Inc. 81
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came from analysis of skewness (Figure S3C), slices with shorter
periods having a more negative skew due to asymmetric distor-
tion of waveform. Our data show that most of the accelerated
degradation of PER within the SCN occurs at a specific phase
and that this acceleration is consistent with, and can account
for, the period changes observed in wheel-running behavior.
CK13tau Selectively Accelerates PER Degradation
Independently of Subcellular Localization
These data indicate that CK13tau accelerates the onset of noctur-
nal processes (but not affecting their absolute duration) by ac-
celerating the clearance of endogenous SCN PER2 proteins
predominantly in the early circadian night. To explore the bio-
chemical basis of this effect, we used real-time fluorescence vid-
eomicroscopy tomonitor PER2::YFP degradation in COS-7 cells
following blockade of de novo protein synthesis by treatment
with cycloheximide (CHX, 20 mg/ml). Coexpression with WT
but not kinase-dead CK13 accelerated PER2::YFP protein deg-
radation, relative to vector control. Degradation was further ac-
celerated by CK13tau (Figure 5A). In contrast, CRY1::CFP degra-
Figure 3. CK13 Mutations Alter Period of SCN Electrical Firing
Rhythm
(A) Representative SCNmultiunit (LH) and single-unit (RH) action potential
discharge rhythms recorded from wild-type (CK13+/+), heterozygote
(CK13+/tau), homozygote (CK13tau/tau) and knockout mutant (CK13/)
brain slices.
(B) Correlation between period of wheel-running behavior determined in
DD before slice preparation and subsequent single-unit SCN firing rates
for WT (closed circles), tau heterozygote (gray circles) and homozygote
(open circles), and null animals (triangles). Data are derived from 11 out
of 13 CK13+/+ SCN neurons, 8/9 CK13+/tau, 11/12 CK13tau/tau, and 9/10
CK13/ cells that exhibited detectable firing-rate rhythms.
dation was not affected by any variants of CK13, indicating
a selective action of CK13 on PER2 (Figure 5B). Inhibition
of nuclear export by leptomycin B (LMB) retained PER2::YFP
in the nucleus and slowed its degradation in the presence of
WT CK13. In contrast, LMB did not alter the acceleration of
PER2 degradation by CK13tau (Figure 5C and 5D), confirming
a nuclear site of action of this mutation. LMB could alter deg-
radation rates by blocking PER nuclear export or by altering
trafficking of other components required for PER degrada-
tion. To differentiate between these possibilities, to extend
the range of cell types investigated, and to determine the
effect of CK13tau on PER1, we expressed in NIH 3T3 cells
WT or mutant forms of PER1 in which either the nuclear ex-
port signal was mutated (mtNES) or an additional copy of
the nuclear localization signal was added (+NLS). Bothmuta-
tions trapped most of the PER1 within the nuclear compart-
ment (>65% for mtNES; > 88% for +NLS) as determined by
immunocytochemisty (Figure 5E). CK13tau accelerated deg-
radation, not only of wtPER1 as previously reported (Gallego
et al., 2006) but also of nuclear-trapped PER1 (residual PER1
at 4 hr post-CHX treatment, CK13tau versus WT, 45% and
81% for mtNES; 39% and 66% for +NLS; Figure 5F). In addi-
tion, CK13tau accelerated degradation of another mutant
form of PER1 (PER1 1-823) which lacked the C terminus that con-
tains an active NLS as well as the CRY binding site (Vielhaber
et al., 2001) and retained PER1 predominantly in the cytoplasm
(>87%; Figures 5E and 5F). Together, these in vitro data clearly
show that CK13tau targets both PER1 and PER2 but not CRY1
proteins, and this selective targeting occurs regardless of
nuclear or cytoplasmic localization.
CK13tau Also Selectively Accelerates Endogenous PER
Degradation in Primary Cells and SCN Slices
We extended these studies of recombinant protein stability by
using western blots to examine native PER1 and CRY1 expres-
sion inWT andmutant primary fibroblast cultures. PER1 proteins
typically exhibit two clear bands which represent hypo- (lower
band) and hyperphosphorylated (upper band) forms of PER1
(Lee et al., 2001; Figure 6A). In taumutant fibroblasts, the overall
levels of PER1 were lower than those seen in WT cells. However,
upon treatment with CHX (20 mg/ml), the hyperphosphorylated
forms of PER1 displayed a significantly shorter half-life in taumu-
tant cells than in WT cells (WT, 9.4 hr, versus tau, 4.0 hr, p < 0.05
using nonlinear exponential decay analysis with GraphPad;82 Neuron 58, 78–88, April 10, 2008 ª2008 Elsevier Inc.
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lated PER1 may be preferentially targeted to the proteasome for
degradation (Gallego and Virshup, 2007). In contrast, the overall
expression level and CHX-stimulated decline of CRY1 was unaf-
fected by CK13tau (Figures 6A and 6B). To obtain amore dynamic
view of PER degradation, we then exploited real-time recording
of primary fibroblasts treatedwith CHX at the peak of PER2::LUC
expression. This revealed that CK13tau significantly shortened
(p < 0.01) the half-life of PER2::LUC expression, by ca. 25 min.
Moreover, even though pretreatment with LMB extended the
half-life in both genotypes, CK13tau was still effective at acceler-
ating PER2::LUC degradation (p < 0.01; Figures 6C and 6D), con-
sistent with the recombinant protein studies of a nuclear action
for the mutation. Finally, we tested PER2::LUC degradation in
the physiologically relevant context of the SCN slice, again add-
ing CHX at the peak of circadian expression. As with the fibro-
blasts, loss of PER2::LUC bioluminescence was more rapid in
mutant than WT SCN slices (Figures 6E and 6F), half-life again
being shortened by ca. 25 min. Moreover, the effect of CK13tau
remained following pretreatment with LMB, which had no
significant effect on PER2::LUC clearance in either genotype.
Together, these data demonstrate that CK13tau facilitates the
degradation of endogenous PER (but not CRY) proteins in SCN
and primary cells, and that blockade of nuclear export does
not attenuate the tau phenotype.
Figure 4. CK13tau Has a Global Impact on
Circadian Pacemaking, Accelerating
Molecular Circadian Oscillators in SCN,
Peripheral Tissues, and Primary Fibroblasts
(A) Representative PER2::LUC bioluminescence
oscillations in WT (red), heterozygote (green),
and homozygote (blue) organotypic SCN slices.
(B) Theperiodicityof tissues fromWT,heterozygote,
and homozygote tau PER2::LUC mice (mean ±
SEM;WT, n=4–6;heterozygotes, n=10–11; homo-
zygote, n = 5–6).
(C) CCD recordings of SCN PER2::LUC expression
at the single cell level for WT and homozygote SCN
slices (20 per slice; n = 3 slices for each genotype).
(D) Representative traces of PER2::LUC expression
in primary fibroblast cultures of WT (red) and tau
mutant (blue) mice.
(E) Waveform alignments by nadir or peak for
PER2::LUC rhythms fromWT (red) andhomozygote
(blue) organotypic SCN slices. Data were normal-
ized and then plotted as mean ± SEM (n = 6 per
genotype). Note selective reduction in peak to nadir
interval regardless of alignment.
Conclusions
In mammals, different forms of CK1
(CK13 and CK1d), act on diverse path-
ways, including Wnt signaling, neuro-
transmitter regulation, as well as circa-
dian rhythms. Both CK13 and CK1d
complex with PER and CRY (Lee et al.,
2001), while CK1-mediated phosphoryla-
tion of BMAL1 increases its transcrip-
tional activity (Eide et al., 2002). In hu-
mans, circadian familial advanced sleep disorders (FASPS) are
known to be caused by a serine to glycine substitution in the
hPer2 gene at position 662 (Toh et al., 2001) and also by
a T44A missense mutation in human Ck1d, which causes hypo-
phosphorylation of PER2 (Xu et al., 2005). Transgenic mice over-
expressing the hPER2 mutation exhibit shorter free-running
periods, mimicking FASPS (Xu et al., 2007), and their phenotype
is sensitive to CK1d: increased dosage of CK1d shortens their
period further. These studies, together with recent in vitro analy-
ses of the equivalent serine residue on mouse PER2 protein
(Vanselow et al., 2006) suggest that expression, degradation, nu-
clear entry and export of PER2 are modulated by multiple states
of phosphorylation and that CK1 activity plays a central role at
these various checkpoints of the circadian cycle (Gallego and
Virshup, 2007; Mignot and Takahashi, 2007).
By creating null and taumutations of CK13 in mice, we provide
behavioral, neurophysiological, and cellular evidence showing
that CK13tau acts as a gain of function that accelerates the mo-
lecular dynamics of circadian time-keeping. These biochemical
actions explain the behavioral and physiological phenotype of
the mutation in both hamsters and mice. They also provide
a new perspective with which to understand the action of
PER2 and CK1 mutations which have been linked to circadian
period and sleep disturbances in humans (Xu et al., 2005,
2007). Our data therefore confirm and extend the earlierNeuron 58, 78–88, April 10, 2008 ª2008 Elsevier Inc. 83
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(A and B) Decay of PER2::YFP or CRY1::CFP fluorescence in COS-7 cells cotransfected with WT (red), tau (Tau, blue), kinase-dead (KD, green) CK13 or empty
plasmid (NC, black). Cells were treated with CHX (20 mg/ml) 0.5 hr before recording.
(C) Decay of PER2::YFP fluorescence in COS-7 cells treated with vehicle or leptomycin B (LMB, 10 ng/ml) 1 hr before CHX (20 mg/ml) (red, CK13 WT + vehicle;
yellow,WT+ LMB; blue, taumutant + vehicle; green, taumutant + LMB). ([A–C] individual cell data normalized to maximum andminimum intensity over recording,
plotted as mean ± SEM, n = 14–33, 2–4 independent experiments).
(D) Half-lives for PER2::YFP in presence of WT or tau CK13, treated with vehicle or LMB (mean ± 95% confidence limits, ***p < 0.001).
(E) Differential nuclear or cytoplasmic retention of Myc-tagged WT and mutant PER1 in NIH 3T3 cells. Scale bar = 500 mm.
(F) Western blots of Myc-tagged wild-type mPER1 or with mutated NES (mtNES), with extra NLS (+NLS) or truncated C terminus removing native NLS (1–823),
coexpressed with HA-tagged CK13 WT or tau mutant in NIH 3T3 cells treated with CHX (40 mg/ml). Data shown are representative of at least three separate
experiments.modeling-based studies, later tested in cell-line studies (Gallego
et al., 2006).Moreover, we show that this acceleration is a conse-
quence of enhanced rates of degradation of PER proteins at spe-
cific phases of the circadian cycle i.e., early circadian night, and
that such asymmetric effects on PER degradation are translated
into altered phasing of physiological and behavioral circuits. Our
studies also reveal that CK13tau can act on both nuclear and cy-
toplasmic targets but suggest that within the SCN, CK1-medi-
ated degradation may be primarily a nuclear event, as predicted
by our studies of the hamster mutant (Dey et al., 2005). We also
show that the knockout of Ck13 has a relatively mild phenotype
(extends the circadian period by ca 18min a day) and that a single
wild-type allele offer no significant protection in the presence of84 Neuron 58, 78–88, April 10, 2008 ª2008 Elsevier Inc.the tau allele. A clear implication therefore is that CK1d may
phosphorylate target PERIOD proteins and that wild-type CK13
may thus be partially redundant in the circadian timing mecha-
nisms. Resolution of these issues awaits characterization of
the phenotypes of Ck1d knockouts.
An intriguing feature of our data is that the duration of molec-
ular night is relatively compressed due to the accelerated clear-
ance of PER2 after its peak expression at CT12, but the duration
of nocturnal behavioral and physiological processes (CBT, mel-
atonin secretion) is apparently normal, asmeasured in solar time.
Consequently, because the offsets are not governed by the mo-
lecular cycle, they occur several hours later than the compressed
molecular cycle would predict: nocturnal processes spilling over
Neuron
Accelerated Molecular Clockwork in tau Mutant MiceFigure 6. Degradation of Endogenous PER Is Accelerated in Tissue and Cells from tau Mutant Mice
(A) Representative western blots of endogenous PER1 and CRY1 in lung fibroblasts fromWT or taumice, treated with CHX (20 mg/ml) for 0, 1, 2, 4, and 6 hr. Note
two distinct bands for PER1.
(B) Group data (mean ± SEM, red = WT, blue = mutant) from western blots reveal significant reduction in expression and earlier clearance of PER1 in mutant
fibroblasts (F test, p < 0.05 for upper band) but no effect of tau on expression of endogenous CRY1 (F test, p = 0.39).
(C) Decay of PER2::LUC bioluminescence from lung fibroblasts, exposed to CHX in presence or absence of LMB. Data are normalized to the peak level
of expression (time 0 after CHX) and the minimum after 8 hr and plotted as mean ± SEM; red = WT + vehicle, black = WT + LMB, blue = tau + vehicle,
green = tau + LMB).
(D) Half-lives for PER2::LUC bioluminescence from fibroblasts (mean ± SEM). CK13tau significantly accelerated loss of PER2::LUC signal regardless of LMB
treatment. **p < 0.01 by t test.
(E) Decay of PER2::LUC bioluminescence from SCN slices, exposed to CHX in the presence or absence of LMB. Data expressed as in (C).
(F) Half-lives for PER2::LUC bioluminescence from SCN slices (mean ± SEM). CK13tau significantly accelerated loss of PER2::LUC signal regardless of LMB
treatment. **p < 0.01 by t test.into the start of the molecular day. Hence the behavioral day (de-
fined by activity offset and onset) is shorter in the mutant, even
though the underlying determining change is shortening of the
molecular night. These strongly asymmetric effects of CK13tau
on molecular and behavioral timing likely underlie the pro-
nounced disturbances of circadian timekeeping (damped ampli-
tude, altered phasing) widely observed in the peripheral tissues
of tau mutant hamsters (Dey et al., 2005) and may contribute
to poor growth and general morbidity associated with the muta-
tion in hamsters (Lucas et al., 2000). The variable responses of
peripheral tissues to the tau mutation are intriguing and may
suggest tissue-specific differences in the relative expression of
CK13 or CK1d, or cellular differences in the manner in which
PERIOD proteins are trafficked and degraded.
Endogenous PER (but not CRY) proteins (PER1 by western
blot, PER2 by bioluminescence recording) are destabilized in
the taumutant background. These effects on protein half-life oc-
cur in a context (treatment with cycloheximide) where transcrip-
tion is irrelevant and thus the observed protein instability is suf-
ficient to explain the behavioral phenotype in full. This point isreinforced by our original findings in the tau mutant hamster
(Dey et al., 2005) which showed that the Per mRNA cycle in
the SCN mapped to circadian time whereas the PER protein ex-
pression cycle was accelerated in vivo due to early clearance.
These results from the kinase mutants therefore provide a valu-
able counterpoint to those of Xu et al. (2007), who modeled
human FASPS by creating mice carrying transgenes encoding
mutated versions of the human PER2 protein. The S662G muta-
tion in hPer2, which leads to one form of FASPS in patients,
shortened circadian period but the apparent degradation rate
of PER2 protein was unaltered. Rather, expression of hPer2
mRNA was reduced, leading to lower hPER2 protein levels.
Our findings with the kinasemutant therefore add further support
to the speculation of Xu et al. (2007) that effects mediated via
S662 may accelerate the clock by reduced transcription,
whereas the taumutation, as a gain-of-function of CK13, targets
a separate domain within PER2 which is responsible for acceler-
ated degradation.
The lack of impact of CK13tau on CRY dynamics complements
the recent description of loss-of-function mutations on F boxNeuron 58, 78–88, April 10, 2008 ª2008 Elsevier Inc. 85
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Accelerated Molecular Clockwork in tau Mutant Miceproteins, whichmediate actions onCRYdegradation, resulting in
a longer half-life of CRY proteins (Godinho et al., 2007; Busino
et al., 2007; Siepka et al., 2007). As a result, circadian period is
lengthened. These studies and data reported here further sug-
gest that mechanisms for the degradation of these two core cir-
cadian transcription factor families (PER and CRY) operate inde-
pendently but must have tightly coevolved in order to achieve
precise overall control on circadian period. Our new mouse
model therefore provides new insight into how a circadian muta-
tionacceleratesbehavioral andcellular circadian rhythms, inboth
the brain and peripheral tissues, and demonstrates that tempo-
rally specific effects on PER degradation can be tracked through
to an altered circadian structure of behavior and physiology.
EXPERIMENTAL PROCEDURES
Animal Maintenance
All experiments were conducted under the aegis of the 1986 Home Office An-
imal Procedures Act (UK) and following local ethical review. All animals were
reared at 20C–22C and maintained on standard rodent breeder or mainte-
nance chow under 12 hr light:12 hr dark lighting schedules.
Antibodies and Plasmids
Monoclonal anti-CK13 antibody was obtained from BD Transduction Labora-
tories, and anti-Myc (9E10) antibody from Santa Cruz Biotechnology. Anti-
PER1 and Anti-CRY1 antibodies were a kind gift fromChoogon Lee. Polyclonal
anti-Myc antibody (9106) was from ABCAM and anti-a-Tubulin (T6199) and
anti-actin (A2066) from Sigma. Myc-PER1 constructs were cloned in
PCS2+MT vector and HA-tagged kinases (CK13 WT and tau mutant) were
cloned in pCEP4 (Invitrogen). The SV40 Tag NLS (PKKKRKVG) was added
to the 50 end of Myc-mPER1 by PCR (Gallego et al., 2006). Full-length
mPer2 cDNA with C-terminal enhanced yellow fluorescent protein tag derived
from pEYFP-N1 (Clontech) was cloned into pcDNA3.1/V5/HisA vector (Invitro-
gen) (PER2::YFP). Full-length mCry1 cDNA was cloned into enhanced cyan
fluorescent protein vector pECFP-N1 (Clontech) (CRY1::CFP). Tau mutation
plasmid for transfection was prepared by site directed mutagenesis leading
to a substitution of arginine 178 (*C*GC) by cysteine (*T*GC). Kinase-dead
variant was prepared by substitution of lysine at position 38 (AAG) by alanine
(GCC). Ck13 plasmid was generously donated by Achim Kramer (Humboldt-
university, Berlin, Germany). Wild-type, tau, or kinase-dead variants of
full-length Ck13 cDNA were cloned into pcDNA-DEST40 vector (Invitrogen)
(WT, Tau, KD).
Generation of Transgenic Mice
The targeting construct contained exons 2–6 of the Ck13 gene (Figure S1) was
prepared using sv129 genomic DNA fragments from a PAC clone. Briefly, an
8.7 kb SalI–XbaI fragment encompassing exons 2–6 was subcloned into
pBluescript (KS+) and verified by end-sequencing. The 1.4 kb BglII–EcoRI
fragment containing exon 4 was used to introduce the taumutation (C12555T)
by site-directed mutagenesis and verified by sequencing. A floxed NeoTK se-
lection cassette was inserted into the EcoRI site in the intron 4, and a double
stranded oligo encoding lox P and NcoI sites ligated into the BglII site 50 of
exon 4 (Figure S1A). The targeting construct was linearized with NotI, electro-
porated into 129/Sv R1 ES cells (http://www.mshri.on.ca/nagy/r1.htm), and
genomic DNA from G418-resistant clones isolated as described previously
(Talts et al., 1999). BglII-digested DNA was Southern blotted and hybridized
with 32P-labeled external probe, amplified from genomic DNA using the follow-
ing primers: forward 50-ACTTCCTTCTCTTTACCCACG-30; reverse 50-AGAAG
CAAGCATCCATTTCC-30. The floxed selection cassette was deleted from
homologously recombined ES cell clones by transient transfection with a
cre-expressing plasmid followed, 48 hr later, by 5 days of FIAU (1-(2-deoxy-
2-fluoro-b-D-arabino-furanosil)-5-iodouracil) selection (Abuin and Bradley,
1996). FIAU-resistant colonies were expanded and genomic DNA analyzed
by PCR as described below to determine whether they were tau or knockout86 Neuron 58, 78–88, April 10, 2008 ª2008 Elsevier Inc.alleles. ES cell clones carrying the tau allele (tau/+) were used to create germ-
line-transmitting chimeras by blastocyst injection. tau/+ mice were crossed
with littermates to produce homozygous tau offspring allele or crossed with
a deletor cre line to generate the Ck13 knockout allele in vivo. Wild-type (+)
and tau alleles were genotyped by PCR using primers ‘‘a’’ (50-CACCTGGGC
ATTGGTGAGT-30 ) and ‘‘b’’ (50-GGAGGTCAAGGGGCCAGT-30) (Figure S1A).
The presence of the knockout () allele was detected using primers ‘‘c’’ (50-
GTGGTAGAAGGAGAGAACTGAC-30) and ‘‘b’’ (see above). In all, 11 chimeric
mice derived from 3 clones were used to generate a founder line of Ck13mice,
which were then introgressed over six generations into a C57/B6 background.
RT-PCR
Total RNA from brain of CK13 knockout mice and wild-type siblings was iso-
lated using Trizol (Invitrogen). To exclude genomic DNA contamination, total
RNA was digested with DNase I (Roche). One microgram of total RNA was re-
verse transcribed using Oligo-dT oligonucleotides by the SuperScript II RNase
H-Reverse Transcription kit (Invitrogen). In parallel, negative control samples
lacked Reverse Transcriptase. Two microliters of the resultant first strand
cDNA was PCR amplified with appropriate primer pairs using a hot-master
PCR kit (Eppendorf) as follows: (1) 96C for 5 min; (2) 30 3 94C for 20 s,
55C for 10 s, 72C for 50 s; (3) 72C for 7 min. PCR products were visualized
on 1.5%agarose gel. Primer pairs were based onmouse sequences as follows
(all 50–30): Ck13 forward, GCCTCTGGTGAGGAAGTAG; reverse, CGGTAGG
GAATATGCTGGTG. Gapdh forward, CCTTCATTGACCTCAACTAC; reverse,
GGAAGGCCATGCCAGTGAGC.
Western Blotting of CK13
Protein extracts were prepared from whole brain of wild-type, CK13 knockout,
and CK13tau/tau mice. Mice were euthanized by cervical dislocation; whole
brains were removed and frozen on dry ice. Tissues were mechanically
homogenized at 4C in three volumes of extraction buffer (0.1 M KCl, 20 mM
HEPES [pH 7.5], 5 mMEDTA, 1mM dithiothreitol, 0.1% Triton X-100, 5% glyc-
erol, 0.5 mM phenylmethylsulfonyl fluoride [PMSF], 1 mM MgCl2, 10 mg/ml of
aprotinin, 5 mg/ml of leupeptin, 1 mg/ml of pepstatin A). Homogenates were
cleared by centrifugation (23 10 min, 13,000 3 g at 4C). Supernatants were
mixed with 23 protein loading buffer, boiled, and spun at 13,000 3 g for
1 min at room temperature. Total protein (70 mg) was resolved on 10% dena-
turing PAGE gels and transferred to nitrocellulose membrane (Bio-Rad). Mem-
branes were blocked with 5% skimmed milk in Tris-buffered saline containing
0.05% Tween 20 and incubated with relevant antibodies. ECL plus detection
was used (Amersham Biosciences).
Behavioral Analysis
Six- to sixteen-week-oldmicewere single-housed in cages equippedwith run-
ningwheels and ad libitum food andwater, containedwithin a light-tight cham-
ber at constant temperature (C) and humidity (%H2O). Mice were entrained to
a 12hr light and 12 hr dark (LD) cycle for 7 days and released into constant
darkness (DD) for 28 days. Wheel revolutions were recorded in 10 min time
bins by DataQuest III acquisition program (Data Sciences Inc.), transferred
to the TauActo 1.2 analysis software (developed in house by T. Brown) to pro-
duce double-plotted actograms, periodogram, intensity of running(alpha/rho),
and power of rhythm. c2 periodogram analyses were performed using 28 days
of data in DD.
Electrophysiological Recordings
Electrophysiological recordings were conducted and analyzed as previously
described (Brown et al., 2006). Mice (housed with running wheels in DD)
were killed at the beginning of the inactive phase, and coronal brain sections
(350 mm thick) were cut using a vibroslicer (Campden Instruments) and
transferred to an interface style brain slice chamber continuously perfused
(1.5 ml/min) with oxygenated (95% O2/5% CO2) aCSF supplemented with
0.0005% gentamicin (Sigma) and warmed to 36C ± 1C. Extracellular multi-
unit activity (MUA, signal-to-noise > 2:1) was recorded from the SCN using
aCSF-filled suction electrodes, differentially amplified (320,000) and band-
pass filtered (300–3000 Hz) via a Neurolog system (Digitimer), digitized
(25,000 Hz) using a micro 1401 mkII interface (Cambridge Electronic Design
[CED]), and recorded on a PC running Spike2 version 5 software (CED).
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of waveform shape and validated by measurement-based clustering and the
presence of a clear refractory period in an interspike interval histogram. Firing
rate data were moderately smoothed using a 1 hr moving average and pre-
sented as the mean firing rate each min. The circadian period of single-cell
and MUA rhythms were analyzed by curve-fitting developed in-house (Clock-
wise; Dr. T. Brown). Initially, data were normalized such that data spanned a
range of values between 100 and 100. The normalized data were then fit
with the equation Y = Asin(B(x+C)) using the Newton-Raphson iterative
method, where A equaled the amplitude of the rhythm, B equaled the period
in radians/hr and C determined the phase. Initial values of A, B, and C were
estimated from the best fitting curve of a series of >3000 standard curves
that spanned the period range 3–34 hr and exhibited a range of different ampli-
tudes and phasing. Peak widths were defined as the duration over which firing
rate was above the mean for that cell.
Metabolic Rhythm Measurement and Analysis
Indirect Calorimetry
Tau and WT mice (n = 6 per genotype) were single-housed in indirect calori-
metric cages (Columbus Instruments). Mice were monitored for a minimum
of 10 days in LD followed by a minimum of 5 days in constant light (LL), during
which time oxygen consumption (VO2) was measured every 10 min. Illustra-
tions of VO2 traces in Figure 2 depict group (genotype) averages taken from
a representative experiment.
Analysis of Metabolic Rhythms
Circadian rhythms in VO2 were analyzed using curve-fitting software (Clock-
wise) as described above. Recordings from individual animals during LD and
LL portions of the experiment were analyzed separately. Once period length
was determined, a composite circadian cycle of metabolic rate was generated
for each animal from the entire test period (a separate composite was gener-
ated for each lighting condition). From these representative circadian profiles,
‘‘active’’ and ‘‘inactive’’ portions of the cycle were determined by normalizing
metabolic rate to the midpoint (50%) of the peak to trough amplitude, calcu-
lated separately for the rise and fall of the rhythm. Duration of active and in-
active phases in LD and LL was analyzed using repeated-measures two-way
ANOVA, with a Bonferonni’s post hoc test.
Bioluminescence Recording and Imaging
Whole-slice bioluminescence emission and individual cellular emission were
recorded as described (Maywood et al., 2006; Prosser et al., 2007) using pho-
tomultiplier assemblies and CCD cameras supplied by Hamamatsu. Wave-
forms of rhythmic bioluminescence emission from whole slices and individual
cells were analyzed in BRASS software and RAP algorithm.
Cell Isolation, Culture, and Transfection
For culture of primary lung fibroblast, lungs were removed from euthanized
adult mice for peripheral fibroblast preparation. Briefly, lung was chopped
and minced in sterile conditions and washed twice in chilled modified Hank’s
Balanced Salt Solution (Sigma). Cells were then dissociated bymeans of shak-
ing at 37C for 2 hr in 100 u/ml of Collagenase IA (Sigma) (dissolved in PBS) and
3mMCaCl2. Once dissociated, cells were filtered through a sterile nylon mesh
followed by two washes and centrifugation in chilled Hank’s solution. Pellets
were resuspended in culture medium (DMEM with 4.5 g/l glucose, Glutamax,
and pyruvate, supplementedwith 10%FBS, 100U/ml Penicillin, and 100 mg/ml
streptomycin) and plated on a 10 cm culture dish. Cultures were maintained at
37C (5% CO2) for 2–3 days until confluent and ready for splitting. Confluent
cells in 35 mm dishes were synchronized with Dexamethasone (100 nM) for
1 hr prior to PMT recording of PER2::LUC bioluminescence (Izumo et al., 2003).
NIH 3T3 cells were grown in DMEM supplemented with 10% calf serum and
antibiotics. At 90% confluence in 6-well plates, cells were transfected with
relevant plasmid combinations using Lipofectamine 2000 (Invitrogen). The
amount of transfected DNA was 0.8 mg of Myc-Per1 and 0.4 mg encoding
HA-tagged kinases for each well. COS-7 cells were grown in DMEM supple-
mented with 10% calf serum and antibiotics. At 80%–90% confluence in
glass-bottomed dishes (MatTek), cells were transfected with combinations
of relevant plasmids using 3 ml of GeneJuice (Novagen). The total amount of
transfected DNA was 1 mg (0.6 mg of Per2::YFP + 0.4 mg of CK1 3 or 0.5 mgof Cry1::CFP + 0.5 mg of CK13) for each dish. Twenty-four hours after transfec-
tion, DMEM was exchanged for air medium and subjected to live cell fluores-
cent imaging (Maywood et al., 2006).
Protein Degradation Assay
For real-time monitoring of PER2::YFP and CRY1::CFP degradation, COS-7
cells were treated with 20 mg/ml cycloheximide (Sigma), with or without LMB
pretreatment (10 ng/ml for 1 hr; Calbiochem). Fluorescence was recorded
every 15 min for at least 17 hr by time-lapse microscopy using Openlab soft-
ware (Improvision, Warwick, UK). Single cell fluorescent data were analyzed
by IPlab software (Scanalytics, B.D. Bioscience, Rockville, MD) and one-
phase exponential decay curve fitting. Half-life calculations and statistics
were performed in Prism (GraphPad Software). Data were plotted as mean ±
SEM with fitted exponential decay curve. Half-lives are plotted as mean ±
95% confidence interval of exponential decay curve fitting.
For detection of Myc-tagged PER1 degradation by western blotting, 20 hr
after transfection, cells were treated with CHX (40 mg/ml) for 0, 2, and 4 hr
and then lysed in lysis buffer (150mMNaCl/20mMHEPES [pH 7.5]/0.1%Non-
idet P-40/1 mM EDTA/2 mM DTT) supplemented with 13 Complete protease
inhibitor mixture (Roche Applied Science). The cells were then mechanically
sheared, and lysates were centrifuged at 16,000 3 g for 10 min at 4C. Total
protein (100 mg) was resolved in SDS/PAGE and then subject to western blot-
ting. For endogenous PER1 and CRY1 degradation, primary lung fibroblasts
were treated with CHX (20 mg/ml) for 0, 1, 2, 4, and 6 hr then subjected to west-
ern blotting using anti-PER1 and anti-CRY1 antibodies. These experiments
were duplicated. For real-time monitoring of PER2::LUC degradation by
PMT, SCN slices or lung fibroblasts were treated with CHX (40 mg/ml) with
or without LMB pretreatment (10 ng/ml for 1 hr). For control experiments,
DMSO (for CHX) or ethanol (for LMB) was used as vehicle.
Immunostaining of PER1 and Mutants in NIH 3T3 Cells
Twenty hours after transfection of different PER1 constructs, cells were re-
plated on glass coverslips. Twenty-four hours later, cells were washed three
timeswith phosphate-buffered saline (PBS) and fixedwith 3.7%paraformalde-
hyde for 15 min. After three more washes, cells were permeabilized with 0.1%
Triton X-100 in PBS for 5 min and washed with 3% BSA/0.1% TX-100/PBS for
30 min. Cells were incubated with an anti-Myc polyclonal antibody for 1 hr in
3%BSA/0.1%TX-100/PBS,washed three times, and incubatedwithasecond-
ary Alexa Fluor 594 goat anti-rabbit IgG (Molecular Probes, Inc.) for 1 hr. Cells
were washed three and incubated with DAPI (1 mg/ml) in 0.1% TX-100/PBS.
Cells were visualized using an Olympus AX70 fluorescence microscope (mag-
nification3 60), and images were digitally recorded via an AxioCam (Carl Zeiss
MicroImaging, Inc.) and saved using the AxioVision 3.1 program. Overlays of
the immunofluorescence images were performed in Photoshop (Adobe).
SUPPLEMENTAL DATA
The Supplemental Data for this article can be found online at http://www.
neuron.org/cgi/content/full/58/1/78/DC1/.
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